-
Revumenib prescribing information
absolute neutrophil count; ANC; acute leukemia; ALL; alloSCT; AML; adverse event management; AE; AUGMENT 101; AUGMENT-101; black box; differentiation syndrome; DS; dose; efficacy; exposure response; HSCT; inducer; inhibitor; interaction; interactions; KMT2A; KMT2Ar; KMT2At; lymphoblastic; management; mechanism; mixed phenotype; mixed-phenotype; MOA; monotherapy; MPAL; pediatric; pediatrics; peds; pharmacokinetics; pk; QT; QTC; rearranged; refractory; relapsed; Revuforj; tdp; torsade;…
-
Aldoss et al. Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia. Presented at EHA 2025
-
Revumenib – Use in Pediatrics
peds; pediatric; pediatrics
-
Revumenib – Safety Data Sheet
sds; safety data sheet; msds
-
Revumenib – AE Management Standard Response Letter
adverse; adverse event; adverse event management; management; differentiation; syndrome; qt; qtc
-
Revumenib – QTc Prolongation
QT; QTC; rearranged; refractory; relapsed; Revuforj; tdp; torsade; torsades;
-
Revumenib – Pharmacokinetics
area; AUC; exposure response; interaction; interactions; pharmacokinetic; pharmacokinetics; pk; poppk
-
Revumenib – Monotherapy in Patients with KMT2Ar R/R Acute Leukemia
monotherapy; kmt2a; kmt2ar; kmt2a translocation; kmt2a translocated; AUGMENT-101; NCT04065399; relapsed; refractory; all; aml; myeloid; lymphocytic; lymphoblastic
-
Revumenib – Monotherapy in Relapsed / Refractory NPM1m Acute Myeloid Leukemia
npm1m; npm1; monotherapy;AUGMENT-101; NCT04065399; relapsed; refractory; aml; myeloid
-
Issa et al. J Clin Oncol. 2025 Jan;43(1):75-84. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).